Revenue Breakdown
Composition ()
No data
Revenue Streams
Evogene Ltd (EVGN) generates its revenue primarily from Agricultural Crops, which accounts for 100.0% of total sales, equivalent to $4.41M. Understanding this concentration is critical for investors evaluating how EVGN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Evogene Ltd maintains a gross margin of 49.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -870.19%, while the net margin is -874.68%. These profitability ratios, combined with a Return on Equity (ROE) of -564.80%, provide a clear picture of how effectively EVGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, EVGN competes directly with industry leaders such as AKTX and GRDX. With a market capitalization of $7.53M, it holds a significant position in the sector. When comparing efficiency, EVGN's gross margin of 49.68% stands against AKTX's N/A and GRDX's N/A. Such benchmarking helps identify whether Evogene Ltd is trading at a premium or discount relative to its financial performance.
